Semaglutide Does Not Cause Depression or Suicidal Thoughts — STEP Trials Post Hoc Analysis of 3,681 People
Post hoc analysis of STEP 1, 2, 3, and 5 trials (3,681 participants) found semaglutide 2.4 mg did not increase depression or suicidal ideation and was associated with a small reduction in depressive symptoms vs placebo.
Quick Facts
What This Study Found
Semaglutide 2.4 mg did not increase depression (PHQ-9 treatment difference -0.56, p<0.001) or suicidal ideation (≤1% both groups) vs placebo across STEP 1, 2, 3, and 5 trials in participants without major psychopathology.
Key Numbers
Pooled data from STEP 1, 2, 3, and 5 trials; semaglutide 2.4 mg weekly vs. placebo; psychiatric adverse events assessed.
How They Did This
Post hoc analysis of pooled data from 4 randomized, double-blind, placebo-controlled STEP trials (3,377 from STEP 1-3 at 68 weeks + 304 from STEP 5 at 104 weeks). PHQ-9 for depression, Columbia-Suicide Severity Rating Scale for suicidal ideation.
Why This Research Matters
Media reports and regulatory inquiries raised concerns about GLP-1 drugs and mental health. This analysis of the largest semaglutide weight management dataset provides robust evidence that semaglutide is psychiatrically safe — and may even slightly improve mood.
The Bigger Picture
As GLP-1 drugs reach tens of millions of users, psychiatric safety data is essential for public confidence. This analysis provides the largest and most rigorous assessment to date, finding no signal for psychiatric harm and a small signal for potential mood benefit.
What This Study Doesn't Tell Us
Post hoc analysis — not designed as a psychiatric safety trial. Excluded participants with known major psychopathology at baseline. PHQ-9 improvement of -0.56 is statistically significant but not clinically meaningful. Short to medium follow-up. Does not address patients with pre-existing mental health conditions.
Questions This Raises
- ?Is semaglutide safe for patients WITH pre-existing depression or other psychiatric conditions?
- ?Does the small mood improvement reflect direct neurological effects of semaglutide or the psychological benefit of weight loss?
- ?Are the psychiatric safety findings generalizable to higher semaglutide doses or oral formulations?
Trust & Context
- Key Stat:
- No psychiatric risk increase Semaglutide 2.4 mg showed no increase in depression (PHQ-9) or suicidal ideation vs placebo across 4 STEP trials
- Evidence Grade:
- Strong evidence — large pooled post hoc analysis from well-designed RCTs with validated psychiatric assessments. Limited by exclusion of patients with baseline psychopathology.
- Study Age:
- Published in 2024. Addresses timely concerns about GLP-1 drug psychiatric safety.
- Original Title:
- Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
- Published In:
- JAMA internal medicine, 184(11), 1290-1300 (2024)
- Authors:
- Wadden, Thomas A(5), Brown, Gregory K, Egebjerg, Christina, Frenkel, Ofir, Goldman, Bryan, Kushner, Robert F, McGowan, Barbara, Overvad, Maria, Fink-Jensen, Anders
- Database ID:
- RPEP-09455
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide cause depression or suicidal thoughts?
No — this analysis of nearly 3,700 people from four major clinical trials found that semaglutide did not increase depression or suicidal thoughts compared to placebo. In fact, there was a small (though not clinically meaningful) improvement in depressive symptoms in the semaglutide group.
Should I worry about my mental health if I'm taking Wegovy?
Based on this evidence, semaglutide does not increase psychiatric risk in people without pre-existing major mental health conditions. However, anyone on any medication should report new mood changes to their doctor. If you have a diagnosed psychiatric condition, discuss your specific situation with your prescriber.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09455APA
Wadden, Thomas A; Brown, Gregory K; Egebjerg, Christina; Frenkel, Ofir; Goldman, Bryan; Kushner, Robert F; McGowan, Barbara; Overvad, Maria; Fink-Jensen, Anders. (2024). Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.. JAMA internal medicine, 184(11), 1290-1300. https://doi.org/10.1001/jamainternmed.2024.4346
MLA
Wadden, Thomas A, et al. "Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.." JAMA internal medicine, 2024. https://doi.org/10.1001/jamainternmed.2024.4346
RethinkPeptides
RethinkPeptides Research Database. "Psychiatric Safety of Semaglutide for Weight Management in P..." RPEP-09455. Retrieved from https://rethinkpeptides.com/research/wadden-2024-psychiatric-safety-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.